R&D The post-Covid New Normal: a golden opportunity for the NHS? I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘
News ADA: AZ reveals oral GLP-1 data in obesity, diabetes AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
